A NON-RANDOMIZED, CONSECUTIVE ENROLLMENT EVALUATION OF THE DESolveTM MYOLIMUS ELUTING BIORESORBABLE CORONARY STENT SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2017
At a glance
- Drugs Myolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions
- Acronyms DESolve-I
- Sponsors Elixir Medical Corporation
- 16 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016 as per ClinicalTrials.gov record.
- 19 Mar 2014 New source identified and integrated.ClinicalTrials.gov record
- 16 May 2012 Lead Investigator (Verheye S) added.